Abbott: Clean, Accessible Water for a Healthy Future

Abbott

Water sustains life, health, and ecosystems. It's a vital resource for a global healthcare company striving to help people around the world live healthier, fuller lives.

But water availability and quality are facing global challenges due to factors like population growth, climate change, industrial expansion, and intensive agriculture. The United Nations predicts a 40% global shortfall of water by 2030 - and it warns that 2.3 billion people around the world don't have adequate access to water and soap for handwashing, critical for a healthy existence.

Water is critical in our efforts to innovate life-changing healthcare technologies. We are committed to efficiently and responsibly managing our water use wherever we work to minimize our impact on local resources.

Our approach is four-fold: improve water efficiency, manage water discharges, apply key water-management practices companywide, and educate our employees and suppliers about the importance of responsible water use.

As part of our 2030 Sustainability Plan, we committed to:

  • Achieve water stewardship certification at all high-water-impact manufacturing sites in water-stressed areas.
  • Implement accredited water stewardship management practices in more than 75% of all manufacturing sites operating in water-stressed areas.
  • Work with 50 key suppliers in high water-stressed areas to reduce water quality and quantity risks to Abbott and the community.

We've been focused on responsible water usage for decades and these goals are meant to target our efforts at making the most impact. We're proud to be making progress and on track to meet these goals by 2030.

Assessing the Environment

Each year, we perform a mapping process to understand where the water we use comes from, how it's treated and discharged and the impact our operations have on local supply. During this process, Abbott has identified 24 of our manufacturing sites globally that operate in water-stressed areas.

In response, we've become a member of the Alliance for Water Stewardship (AWS), a global collaboration of businesses and NGOs that contribute to the sustainability of local water resources. Two Abbott sites in high-water-impact and water-stressed areas - in California and Spain - received important AWS certification in 2022 and four others in California, Chile, India, and Singapore are working toward certification. Five more sites are slated to pursue future certification during the plan's course.

Thirteen additional Abbott manufacturing sites in areas considered water-stressed but not in high water impact also started implementing water stewardship practices last year.

Partnering for Greater Impact

It will take everyone working together to make the biggest impact in water stewardship. That's why partnership is part of our approach and why, for example, we engage our suppliers in high water-stressed areas to work with us to reduce risks to water quality and quantity. So far, we've engaged 26 Abbott suppliers from water-stressed locations to identify water management opportunities and have piloted more robust partnerships with five key suppliers to reduce our shared-water impacts.

As part of our AWS certification efforts, Abbott also works with local communities to solve shared water challenges because successful water management accounts for local water and biodiversity needs. This means identifying opportunities to have an impact - and acting. For example:

  • Our AWS-certified site in Spain donates empty, bulk containers to a local reforestation nonprofit group, supporting irrigation of trees and recycling of the containers.
  • In California our AWS-certified site partners with a waste disposal company to provide compost to a local winery to improve soil conditions.

Looking Forward

We're committed to maintaining sustainable, efficient, and comprehensive water management programs and finding new approaches to upgrade our existing sites and processes to make the most positive impacts on water quality and supply in areas where we operate globally.

As we pursue the goals in our 2030 plan, we'll continue to map our water use and track trends globally, as well as look for new ways to engage our employees and partners in our water stewardship efforts.

See below resources to find out more about Abbott's efforts to manage water usage efficiently and responsibly.

Abbott, Wednesday, March 22, 2023, Press release picture

View additional multimedia and more ESG storytelling from Abbott on 3blmedia.com.

Contact Info:
Spokesperson: Abbott
Website: https://www.3blmedia.com/profiles/abbott
Email: info@3blmedia.com

SOURCE: Abbott



View source version on accesswire.com:
https://www.accesswire.com/745279/Abbott-Clean-Accessible-Water-for-a-Healthy-Future

News Provided by ACCESSWIRE via QuoteMedia

ABT
The Conversation (0)
Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

  • New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials
  • Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation
  • The new programs build on a successful first year of the multi-million-dollar corporate initiative

Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the focus on diversified participants in the company's own clinical trials during the initiative's first year.

The latest programs include the launch of a new initiative with the Norton Healthcare Foundation to build and implement new models of sustainable clinical research alongside the Institute for Health Equity, a Part of Norton Healthcare in Louisville, Ky. ; a new training program for clinical research coordinators in partnership with Barnett International; and a newly-created Diversity in Research Office at Abbott focused on ensuring diverse representation in clinical trials.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
richard murray md

Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, is pleased to announce that the Company has hired Richard K. Murray, M.D., to the newly created position of Chief Medical Officer (CMO).

Dr. Murray has over 25 years of industry experience. He worked at Merck & Co. for many years in positions of increasing responsibility, in a variety of business, medical and scientific areas. His most recent position was Vice President and Deputy Chief Patient Officer. Dr. Murray was also a Fellow at the Advanced Leadership Initiative at Harvard University. He has managed all areas of medical affairs, including outcomes research, medical information, professional and academic affairs, field-based medical physicians, and investigator-initiated trials globally. Prior to his industry career, he was a practicing physician in cardiovascular-pulmonary medicine and an asthma researcher at the Hospital of the University of Pennsylvania. Dr. Murray has an M.D. from Howard University and an M.A. in Chemistry and A.B. in Psychology from Clark University. Dr. Murray currently is Board Chair of the Asthma and Allergy Foundation of America.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×